Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: $OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Olema Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Olema Pharmaceuticals's position in the market.
Olema Pharmaceuticals, Inc. announces new clinical data for Palazestrant in combination with Ribociclib to be presented at the 2024 ESMO Breast Cancer Annual Congress. The company will share information from its ongoing Phase 1b/2 clinical study in a poster presentation. The event will take place in Berlin, Germany, on May 15-17, 2024.
Additionally, Olema will host an investor conference call on May 15, 2024, to discuss the data further. The company focuses on developing targeted therapies for women's cancers, marking a significant milestone in its research and development efforts.
Olema Pharmaceuticals, Inc. announced the granting of stock options to new employees under the Company's 2022 Inducement Plan. A total of 187,400 shares of common stock were granted to six employees, with options vesting over four years. The exercise price is set at $10.40 per share, with the options subject to Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will participate in various investor conferences in May, including the BofA Securities Health Care Conference, H.C. Wainwright BioConnect Investor Conference, UBS Spring Biotech Symposium, and TD Cowen Oncology Innovation Summit. The management team will engage in presentations, fireside chats, and one-on-one meetings to discuss the company's targeted therapies for women's cancers.
